Abstract
Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
| Original language | English |
|---|---|
| Pages (from-to) | 227-230 |
| Number of pages | 4 |
| Journal | Journal of Pediatrics |
| Volume | 214 |
| DOIs | |
| Publication status | Published - Nov 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pediatrics, Perinatology, and Child Health
Cite this
Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease. / Oda, Takuya; Nagata, Hazumu; Nakashima, Yasutaka; Nanishi, Etsuro; Takada, Yui; Nishimura, Manao; Kubo, Eiji; Hatae, Ken; Ohga, Shouichi.
In: Journal of Pediatrics, Vol. 214, 11.2019, p. 227-230.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease
AU - Oda, Takuya
AU - Nagata, Hazumu
AU - Nakashima, Yasutaka
AU - Nanishi, Etsuro
AU - Takada, Yui
AU - Nishimura, Manao
AU - Kubo, Eiji
AU - Hatae, Ken
AU - Ohga, Shouichi
PY - 2019/11
Y1 - 2019/11
N2 - Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
AB - Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
UR - http://www.scopus.com/inward/record.url?scp=85069696876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069696876&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2019.06.018
DO - 10.1016/j.jpeds.2019.06.018
M3 - Article
C2 - 31351682
AN - SCOPUS:85069696876
VL - 214
SP - 227
EP - 230
JO - Journal of Pediatrics
JF - Journal of Pediatrics
SN - 0022-3476
ER -